SCHEMBL4831152

SCHEMBL4831152

CC(C)(C)OC(=O)CC(CCP(=O)(OCc1ccccc1)OCc1ccccc1)C(=O)N1C(=O)OCC1Cc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 6/20 0.39
PPARG P37231 2/20 0.35
FAAH O00519 1/20 0.34
PLA2G10 O15496 1/20 0.34
PLA2G5 P39877 1/20 0.34
KLK7 P49862 3/20 0.33
KLK5 Q9Y337 2/20 0.33
IL6ST P40189 1/20 0.33
HDAC1 Q13547 2/20 0.32
USP2 O75604 2/20 0.32
NAAA Q02083 1/20 0.32
FOLH1 Q04609 1/20 0.32
NR1H2 P55055 1/20 0.31
NR1H3 Q13133 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14296457 0.86 PPARA (0.37) PPARAFAAHPLA2G10PLA2G5KLK7
SCHEMBL14321021 0.86 PPARA (0.37) PPARAFAAHPLA2G10PLA2G5KLK7
SCHEMBL14321018 0.86 PPARA (0.37) PPARAFAAHPLA2G10PLA2G5KLK7
SCHEMBL17756153 0.86 PPARA (0.37) PPARAFAAHPLA2G10PLA2G5KLK7
SCHEMBL8554608 0.86 FAAH (0.40) PPARAFAAHPLA2G10PLA2G5KLK7
SCHEMBL8011986 0.86 PPARA (0.39) PPARAFAAHPLA2G10PLA2G5KLK7
SCHEMBL2025733 0.86 KLK7 (0.43) PPARAPPARGFAAHPLA2G10PLA2G5
SCHEMBL6448977 0.86 KLK7 (0.43) PPARAPPARGFAAHPLA2G10PLA2G5
SCHEMBL974301 0.86 KLK7 (0.43) PPARAPPARGFAAHPLA2G10PLA2G5
SCHEMBL17756172 0.86 PPARA (0.39) PPARAFAAHPLA2G10PLA2G5KLK7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365091-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2008-04-29 US disclosed
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX ENOBIA PHARMA (CA) 2006-12-21 US disclosed
US-7105539-B2 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-09-12 US disclosed
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex ENOBIA PHARMA (CA) 2006-06-22 US disclosed
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex BIOMEP INC. 2004-09-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060287280-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of PHEX GLS, SUCNR1, PGD PPARA 1799/4885PPARG 1182/4885FAAH 2423/4885
US-20040186301-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, PGD PPARA 1922/4885PPARG 1228/4885FAAH 2375/4885
US-20060135480-A1 Derivatives of succinic and glutaric acids and analogs thereof useful as inhibitors of phex GLS, SUCNR1, GCDH PPARA 1772/4885PPARG 1112/4885FAAH 2430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.